Clinical Trial Protocol Writing with AI

Clinical trial protocol writing is the most consequential scientific writing function in drug development — and one of the most technically demanding. A Phase II protocol must simultaneously satisfy the scientific requirements of a controlled clinical investigation, the regulatory requirements of ICH GCP and applicable regional guidelines, the ethical requirements of institutional review boards and ethics committees, the operational requirements of clinical sites that must execute the trial, and the statistical requirements that determine whether the study will generate data capable of supporting a Phase III development decision. A protocol that fails on any of these dimensions — endpoints that do not align with regulatory approval requirements, eligibility criteria that make enrolment impossible, a schedule of assessments that is operationally impractical for clinical sites, statistical assumptions that are insufficiently justified — does not just generate protocol amendments. It generates trial delays, regulatory queries, and in the worst cases, study failures that set drug development programmes back by years.

This program builds the complete protocol writing competency stack from the ground up across three tightly integrated operational layers. The first is the regulatory and ethical foundation — understanding what Good Clinical Practice is and why it governs every protocol decision, the ethical framework within which clinical research must operate, the landscape of clinical trial types and study designs relevant to Phase II development, and the documentation standards that apply to GCP-compliant clinical trial records. These are the foundational principles that make every subsequent protocol writing decision regulatory-defensible and ethically sound. The second layer is the complete protocol development curriculum — protocol structure and ICH E6(R2) section requirements, study objective formulation and primary and secondary endpoint selection, study population definition and eligibility criteria development, intervention and dosing strategy documentation, schedule of assessments design, risk assessment and risk mitigation framework, AI-assisted protocol writing tools and validation methodology, protocol amendment management and version control, and statistical considerations including sample size justification, hypothesis testing framework, and analysis population definitions. The third layer is the CRF and data collection framework curriculum — CRF design principles aligned to protocol data collection requirements, data collection methodology standards, missing data handling strategies, and CRF amendment and version control management. These three layers are trained as an integrated protocol authorship system because a clinical trial protocol and its associated CRF are not independent documents — they are a unified data collection specification that must be internally consistent from endpoint definition through data capture design.

By the end you carry a complete Phase II clinical trial protocol package — full protocol document, CRF design, amendment record, and version control documentation — advisor-reviewed and published to your professional portfolio. In clinical research, the ability to demonstrate documented protocol writing capability — an actual protocol rather than a knowledge claim — is the credential distinction that opens the most competitive career pathways across pharmaceutical companies, CROs, and academic clinical research organisations.

You are assigned to the clinical development writing function of a simulated pharmaceutical company. A Phase II proof-of-concept study has been approved for development. The investigational medicinal product has completed Phase I with an acceptable safety profile and pharmacokinetic data supporting the proposed Phase II dose range. Your job is to author the complete Phase II protocol from scientific rationale to submission-ready document:

Begin with the GCP and ethical framework review. What are the ICH E6(R2) mandatory protocol elements for this trial type? What ethical considerations apply to the target patient population — is this a vulnerable population requiring additional safeguards? What study design is most appropriate for Phase II proof-of-concept — randomised controlled, single-arm, crossover, or adaptive? Document the study design rationale with reference to ICH E8 General Considerations.

Open the protocol structure. Build the complete section framework — study rationale and background, study objectives and endpoints, study design, study population, interventions, study procedures and schedule of assessments, statistical considerations, data management, safety monitoring, ethical and regulatory considerations, and administrative information. Each section must be sequenced and internally consistent before content is drafted.

Draft the study objectives and endpoints. The primary endpoint must be clinically meaningful, measurable within the study timeframe, and aligned with the regulatory approval endpoint framework for this indication. Define the primary endpoint with complete operational specification — what is being measured, how, at what timepoint, using which validated instrument or clinical assessment. Define the secondary endpoints in order of priority. Define any exploratory endpoints. Ensure every endpoint specified in this section has a corresponding assessment in the schedule of assessments and a corresponding CRF data capture field.

Draft the eligibility criteria. Inclusion criteria must define the study population with sufficient precision to ensure the enrolled subjects are representative of the intended treatment population, while exclusion criteria must protect subject safety without being so restrictive that enrolment becomes infeasible. Apply risk assessment to the eligibility framework — are there safety signals from Phase I that require specific exclusion criteria? Are the laboratory threshold requirements in the exclusion criteria operationally standardised across potential clinical sites?

Draft the intervention and dosing section. What is the investigational product, what is the dose, what is the route of administration, and what is the dosing schedule? What is the dose modification guidance for adverse events? What are the criteria for treatment discontinuation? What are the concomitant medication restrictions and permissions?

Design the schedule of assessments. Build the assessment schedule table — every study visit, every assessment performed at each visit, every timepoint for safety laboratory testing, every endpoint measurement timeframe. Verify internal consistency — every endpoint specified in the objectives section must have at least one corresponding assessment timepoint in this table. Verify operational feasibility — is the assessment burden at each visit practical for clinical site execution?

Apply statistical considerations. What is the primary hypothesis? What is the statistical test? What sample size is required to achieve 80% power at a 0.05 significance level given the expected effect size? Justify the effect size assumption with reference to available data — Phase I results, literature, or prior studies in the indication. Define the analysis populations — ITT, PP, and safety. Define the approach to missing data. Define the interim analysis plan if applicable.

Conduct the risk assessment. What are the known risks of the investigational product based on Phase I data? What are the potential risks specific to the Phase II study design — first-in-patient population, higher doses than Phase I, longer exposure? What risk mitigation measures are built into the protocol — stopping rules, DSMB oversight, safety monitoring frequency?

Use AI-assisted protocol writing tools. The AI drafting tool generates initial section text for the statistical considerations section and the schedule of assessments table. Review every AI output — verify that the sample size calculation uses the correct statistical assumptions, that the schedule of assessments table is complete against the endpoint list, and that the language meets regulatory writing standards. Accept, modify, or reject each AI output with documented rationale.

Manage a protocol amendment. A safety signal from a concurrent trial in the same drug class requires a new exclusion criterion to be added. Execute the amendment process — draft the amendment document, specify the changed section and the nature of the change, justify the amendment with reference to the safety signal, update the protocol version number, and build the version control record showing the amendment history from version 1.0 to version 1.1.

Design the CRF. Build the CRF data capture pages aligned to the protocol's schedule of assessments — a CRF page for each visit, data fields for each assessment, field specifications that ensure the data collected will support the endpoint calculations defined in the statistical analysis plan. Identify any CRF fields that are missing — endpoints specified in the protocol that have no corresponding CRF capture field. Resolve every gap before the CRF is finalised.